Paolo Tarantino/X
Aug 20, 2025, 19:35
Paolo Tarantino on Investigating Dato-DXd in HER2- Breast Cancer Brain Metastases – VJ Oncology
VJ Oncology shared a post on X:
“Paolo Tarantino of Dana-Farber Cancer Institute on the Phase II DATO-Base trial:
- Dato-DXd in HER2⁻ metastatic breast cancer with brain mets or leptomeningeal disease
- Primary focus: intracranial response + blood and CSF translational analyses
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Associate Editor for Breast Cancer at ESMO Open, shared this post, adding:
“With outcomes for MBC progressively improving in time, the prevalence of patients developing and living with CNS disease is also rising, calling for intracranially active treatments. We plan to present the first results from DATO-Base by the end of the year. Stay tuned!”
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 20, 2025, 18:26
Aug 20, 2025, 17:39
Aug 20, 2025, 17:21
Aug 20, 2025, 17:09
Aug 20, 2025, 16:55